TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00344487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
Study: NCT00540410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)
Description: Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
Study: NCT03781986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-115
Description: APG-115 at 150mg (or lower, if dose is reduced) is taken orally every other day through day 13 of each cycle. Cycle length 21 days.
Study: NCT00540410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem® (arthemether+ lumefantrine)
Description: Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.~Duration of treatment: 3 days
Study: NCT02059291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to canakinumab solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to canakinumab solution for subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to canakinumab solution for subcutaneous injection
Study: NCT06275633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa
Description: Medicine response
Study: NCT01819532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Milking group
Description: The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: The umbilical cord will be clamped and cut immediately after delivery of the neonate.
Study: NCT02411864

Intervention type: OTHER
Intervention: different low b-values distribution

Intervention type: OTHER
Intervention: different low b-values distribution

Intervention type: OTHER
Intervention: different low b-values distribution

Intervention type: OTHER
Intervention: different low b-values distribution
Study: NCT01719744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Study: NCT01433289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
Study: NCT03781986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is given IV at AUC=4.5 on day 1 of each cycle. Cycle length 21 days.
Study: NCT01433289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Description: There will be 3 dose levels and for each dose level, there will be 6 subjects who will receive the study drug and 2 subjects who will be randomized to take placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding dose level will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each dose level is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02902484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
Study: NCT03680118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autogenous rings with GBR and autogenous graft with ti-mesh
Description: * Autogenous Onlay ring block harvested from either mandibular ramus or chin will be placed over the defected site and fixed using titanium screws (1.6mm diameter) and then GBR using autogenous particulate will be placed around and over the blocks and covered with a resorbable bilayer collagen membrane (Bio-Gide®, Geistlich, USA)~* Autogenous bone graft will be placed on the defected site and covered by a titanium mesh which will be fixed by titanium screws.~* Flap advancement will be acquired by releasing the mylohyoid muscle attachment from the lingual flap and periosteal releasing incision for the buccal flap to provide tension free closure.~* The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using horizontal mattress and interrupted 4/0 polypropylene sutures.
Study: NCT02310334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Exercise Session
Description: Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unguided Exercise Session
Description: Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
Study: NCT01579851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: sugammadex~* 4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count~* 2 mg/kg : if there is at least two responses to Train of Four stimulations
Study: NCT00561548

Intervention type: PROCEDURE
Group type: OTHER
Intervention: rectosigmoïdal biopsies
Description: rectosigmoïdal biopsies

Intervention type: PROCEDURE
Group type: OTHER
Intervention: rectosigmoïdal biopsies
Description: rectosigmoïdal biopsies
Study: NCT03867318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin administered orally QD as 10 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin administered orally QD as 10 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe administered orally QD as 10 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ezetimibe
Description: Single placebo tablet administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin
Description: Single placebo tablet administered orally QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Atorvastatin
Description: Single placebo tablet administered orally QD
Study: NCT01383343

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study: NCT04117867

Intervention type: BEHAVIORAL
Intervention: Patiens with intraoperative hypotension
Description: In this study, we will use four previously defined thresholds for intraoperative hypotension: two absolute thresholds (MAP less than 50 mmHg and MAP less than 60 mmHg) and two relative thresholds to the baseline MAP (a decrease of 30% or more and a decrease of 40% or more). A definition of baseline value most frequently reported was the arterial blood pressure before the induction of anesthesia. Therefore, the baseline MAP used in calculating the relative thresholds is defined as the mean MAP of all available blood pressure measurements before induction of anesthesia in the operating room.
Study: NCT04412785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: • The initial dose will be 9 mg/kg/day oral divided q12h. For IV, the dose will be 3mg/kg/day by continuous IV infusion.
Study: NCT02219867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Drug (including placebo)
Study: NCT01161199

Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.

Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.

Intervention type: PROCEDURE
Intervention: Leukapheresis
Description: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
Study: NCT02310867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand transplant
Description: The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
Study: NCT02246413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAINBOW Intervention Program
Description: Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
Study: NCT01649089

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conization
Description: Undergo cone biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Lymphadenectomy
Description: Undergo lymphadenectomy
Study: NCT03120195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The EndoRotor®
Description: The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
Study: NCT02129088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
Study: NCT01950013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory training program
Description: Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Active Control
Description: This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
Study: NCT01659476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine(MCh) Challenge Testing
Description: Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine(MCh) Challenge Testing
Description: Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine(MCh) Challenge Testing
Description: Visit 1: High-dose methacholine challenge test~Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Methacholine(MCh) Challenge Testing
Description: Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.~Visit 2: Subjects will perform the opposite protocol, based on their first visit:
Study: NCT02299791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL
Description: This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.~1. EHR tools to expedite identification~   a. EHR automated point-of-care alerts (Best Practice Alerts)~2. EHR tools to expedite prescribing~   1. EHR order sets~  2. EHR text shortcuts for notation~  3. patient education materials (handout, poster)~3. EHR-based outreach support tools a. EHR registries

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL
Description: These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
Study: NCT01110148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based informed consent for skin biopsies
Description: video-based informed consent for punch and shave biopsies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional informed consent
Description: traditional informed consent (standard of care) from physicians for shave and punch biopsies
Study: NCT05231096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloe-vera gel
Description: Aloe-Vera gel Production Aloe vera gel used in this study was 98% aloe vera gel concentration and 2% normal saline. Preparation of aloe-vera gel consists of ripen leaf of aloe vera.(26) Aloe vera leaf was washed thoroughly under water and then cut from the center and the seeping gel was collected in sterile container and was stored at 4°C until the time of application. In our research this pure Aloe vera gel was extracted by The Pakistan Council of Scientific \& Industrial Research (PCSIR) laboratory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sidr honey
Description: Honey collection Sidr (Beri) honey was used in this study. Honey was thick, raw and cold extracted from remote Pakistan afghan tribal forest belt of Sidr trees. It was smooth, viscous and medium to dark amber in color.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling ans root Debridement
Description: non-surgical periodontal therapy was given to all the participants of all the three groups

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling ans root Debridement
Description: non-surgical periodontal therapy was given to all the participants of all the three groups

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Scaling ans root Debridement
Description: non-surgical periodontal therapy was given to all the participants of all the three groups
Study: NCT02943304

Intervention type: OTHER
Intervention: Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV
Study: NCT00637780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
Study: NCT06035419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: breastfeeding education for migrant mothers
Study: NCT02086513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: Treatment with LDE225
Study: NCT04971317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar-Sweetened Beverage (SSB) Video
Description: Participants will watch a video showing the decay of an egg in various SSBs (Coca-Cola, Sprite, Gatorade, and apple juice), followed by the evaporation of these beverages over a heat source, revealing their sugar content.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water Video
Description: Participants will watch a video showing an egg maintaining its shell in water, followed by the evaporation of water.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will watch a video of an egg maintaining its shell in rubbing alcohol, followed by the evaporation of rubbing alcohol.
Study: NCT01284036

Intervention type: DRUG
Group type: OTHER
Intervention: PF-05230905
Description: Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
Study: NCT00687141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0328
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
Study: NCT00832624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks